← Akzo Nobel NV overview

Akzo Nobel NV vs Chemours: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Akzo Nobel NV (AKZA.AS)

Q3 2026
▲4

AkzoNobel advances $25B Axalta merger, sells SE Asia unit, Q2 profit up

  • Q2 profit rises, full-year targets on track AkzoNobel's Q2 profit rose to €139 million from €124 million, with adjusted EBITDA up to €398 million. Revenue slipped slightly to €2.59 billion, but the company remains on track for full-year targets and expects €100 million EBITDA improvement. This supports the share price by showing steady profitability and progress.

    Earnings growth and target confirmation directly support the investment case and share price.

  • Axalta merger progresses with governance tweaks and strong Axalta results AkzoNobel and Axalta improved merger governance (annual director elections, lower approval threshold) after shareholder talks. Axalta posted record Q2 EBITDA of $305 million and projects $600 million in annual cost synergies. These developments keep the $25 billion merger on track, boosting confidence in future value.

    Merger progress and partner strength are key catalysts for the pending deal and future earnings.

  • AkzoNobel sells SE Asia decorative paints unit to Nippon Paint AkzoNobel agreed to sell its Southeast Asian architectural coatings business to Nippon Paint for $1.35 billion, concluding its strategic review of Asian decorative paints. This simplifies the business and raises cash ahead of the Axalta merger, likely supporting the share price.

    Divestment sharpens focus and strengthens balance sheet before merger, a positive for shareholders.

  • EU set to approve Axalta deal with vehicle-refinish divestments AkzoNobel will offer divestments in vehicle refinish to satisfy EU regulators, and the EC is expected to approve the $25 billion Axalta deal. The powder coating concerns were dropped. This removes a major regulatory hurdle, making the merger completion more likely and supporting the share price.

    Regulatory clearance is a critical step for the merger to close, directly affecting deal certainty and valuation.

August 2026
▲4

AkzoNobel advances $25B Axalta merger, sells SE Asia unit, Q2 profit up

  • Q2 profit rises, full-year targets on track AkzoNobel's Q2 profit rose to €139 million from €124 million, with adjusted EBITDA up to €398 million. Revenue slipped slightly to €2.59 billion, but the company remains on track for full-year targets and expects €100 million EBITDA improvement. This supports the share price by showing steady profitability and progress.

    Earnings growth and target confirmation directly support the investment case and share price.

  • Axalta merger progresses with governance tweaks and strong Axalta results AkzoNobel and Axalta improved merger governance (annual director elections, lower approval threshold) after shareholder talks. Axalta posted record Q2 EBITDA of $305 million and projects $600 million in annual cost synergies. These developments keep the $25 billion merger on track, boosting confidence in future value.

    Merger progress and partner strength are key catalysts for the pending deal and future earnings.

  • AkzoNobel sells SE Asia decorative paints unit to Nippon Paint AkzoNobel agreed to sell its Southeast Asian architectural coatings business to Nippon Paint for $1.35 billion, concluding its strategic review of Asian decorative paints. This simplifies the business and raises cash ahead of the Axalta merger, likely supporting the share price.

    Divestment sharpens focus and strengthens balance sheet before merger, a positive for shareholders.

  • EU set to approve Axalta deal with vehicle-refinish divestments AkzoNobel will offer divestments in vehicle refinish to satisfy EU regulators, and the EC is expected to approve the $25 billion Axalta deal. The powder coating concerns were dropped. This removes a major regulatory hurdle, making the merger completion more likely and supporting the share price.

    Regulatory clearance is a critical step for the merger to close, directly affecting deal certainty and valuation.

Latest
▲4

AkzoNobel advances $25B Axalta merger, sells SE Asia unit, Q2 profit up

  • Q2 profit rises, full-year targets on track AkzoNobel's Q2 profit rose to €139 million from €124 million, with adjusted EBITDA up to €398 million. Revenue slipped slightly to €2.59 billion, but the company remains on track for full-year targets and expects €100 million EBITDA improvement. This supports the share price by showing steady profitability and progress.

    Earnings growth and target confirmation directly support the investment case and share price.

  • Axalta merger progresses with governance tweaks and strong Axalta results AkzoNobel and Axalta improved merger governance (annual director elections, lower approval threshold) after shareholder talks. Axalta posted record Q2 EBITDA of $305 million and projects $600 million in annual cost synergies. These developments keep the $25 billion merger on track, boosting confidence in future value.

    Merger progress and partner strength are key catalysts for the pending deal and future earnings.

  • AkzoNobel sells SE Asia decorative paints unit to Nippon Paint AkzoNobel agreed to sell its Southeast Asian architectural coatings business to Nippon Paint for $1.35 billion, concluding its strategic review of Asian decorative paints. This simplifies the business and raises cash ahead of the Axalta merger, likely supporting the share price.

    Divestment sharpens focus and strengthens balance sheet before merger, a positive for shareholders.

  • EU set to approve Axalta deal with vehicle-refinish divestments AkzoNobel will offer divestments in vehicle refinish to satisfy EU regulators, and the EC is expected to approve the $25 billion Axalta deal. The powder coating concerns were dropped. This removes a major regulatory hurdle, making the merger completion more likely and supporting the share price.

    Regulatory clearance is a critical step for the merger to close, directly affecting deal certainty and valuation.

Chemours Co (CC)

Q3 2026
▲2▼2

Chemours settles PFAS suits, sets 2026 guidance; new state lawsuits add risk

  • EPA PFAS settlement removes major regulatory overhang Chemours agreed to pay a $22.5 million penalty and fund $90 million in PFAS mitigation projects, resolving a major federal dispute. The stock jumped 6.1% on the news as investors saw the settlement as a known cost that clears a big legal cloud, making future cash flows more predictable.

    This is the period's biggest positive catalyst, directly lifting CC shares by reducing uncertainty.

  • New York and other states sue over PFAS contamination New York State sued 3M, DuPont, and Chemours spinoffs over PFAS, seeking cleanup costs and penalties. This adds fresh legal risk and potential future payouts, which can weigh on CC's stock because investors worry about unknown liabilities and cash outflows.

    It introduces a new legal threat that could increase costs and uncertainty for CC.

  • 2026 guidance shows earnings growth and deleveraging Chemours guided 2026 adjusted EBITDA to $775–$825 million and net leverage to about 3.8x, with Q2 beating expectations on pricing strength and cost cuts. This signals improving profits and a stronger balance sheet, supporting a higher stock price as investors gain confidence in the business.

    It provides a forward-looking financial picture that directly influences CC's valuation.

  • Court approves $2.5 billion New Jersey PFAS settlements A federal judge approved over $2.5 billion in PFAS settlements involving DuPont, 3M, Chemours, and Corteva. While this resolves some claims, it confirms large legacy costs for Chemours, which can pressure the stock as investors factor in the cash outflows.

    It finalizes a major liability that affects CC's financial obligations and investor sentiment.

July 2026
▲2▼2

Chemours settles PFAS suits, sets 2026 guidance; new state lawsuits add risk

  • EPA PFAS settlement removes major regulatory overhang Chemours agreed to pay a $22.5 million penalty and fund $90 million in PFAS mitigation projects, resolving a major federal dispute. The stock jumped 6.1% on the news as investors saw the settlement as a known cost that clears a big legal cloud, making future cash flows more predictable.

    This is the period's biggest positive catalyst, directly lifting CC shares by reducing uncertainty.

  • New York and other states sue over PFAS contamination New York State sued 3M, DuPont, and Chemours spinoffs over PFAS, seeking cleanup costs and penalties. This adds fresh legal risk and potential future payouts, which can weigh on CC's stock because investors worry about unknown liabilities and cash outflows.

    It introduces a new legal threat that could increase costs and uncertainty for CC.

  • 2026 guidance shows earnings growth and deleveraging Chemours guided 2026 adjusted EBITDA to $775–$825 million and net leverage to about 3.8x, with Q2 beating expectations on pricing strength and cost cuts. This signals improving profits and a stronger balance sheet, supporting a higher stock price as investors gain confidence in the business.

    It provides a forward-looking financial picture that directly influences CC's valuation.

  • Court approves $2.5 billion New Jersey PFAS settlements A federal judge approved over $2.5 billion in PFAS settlements involving DuPont, 3M, Chemours, and Corteva. While this resolves some claims, it confirms large legacy costs for Chemours, which can pressure the stock as investors factor in the cash outflows.

    It finalizes a major liability that affects CC's financial obligations and investor sentiment.

Latest
▲2▼2

Chemours settles PFAS suits, sets 2026 guidance; new state lawsuits add risk

  • EPA PFAS settlement removes major regulatory overhang Chemours agreed to pay a $22.5 million penalty and fund $90 million in PFAS mitigation projects, resolving a major federal dispute. The stock jumped 6.1% on the news as investors saw the settlement as a known cost that clears a big legal cloud, making future cash flows more predictable.

    This is the period's biggest positive catalyst, directly lifting CC shares by reducing uncertainty.

  • New York and other states sue over PFAS contamination New York State sued 3M, DuPont, and Chemours spinoffs over PFAS, seeking cleanup costs and penalties. This adds fresh legal risk and potential future payouts, which can weigh on CC's stock because investors worry about unknown liabilities and cash outflows.

    It introduces a new legal threat that could increase costs and uncertainty for CC.

  • 2026 guidance shows earnings growth and deleveraging Chemours guided 2026 adjusted EBITDA to $775–$825 million and net leverage to about 3.8x, with Q2 beating expectations on pricing strength and cost cuts. This signals improving profits and a stronger balance sheet, supporting a higher stock price as investors gain confidence in the business.

    It provides a forward-looking financial picture that directly influences CC's valuation.

  • Court approves $2.5 billion New Jersey PFAS settlements A federal judge approved over $2.5 billion in PFAS settlements involving DuPont, 3M, Chemours, and Corteva. While this resolves some claims, it confirms large legacy costs for Chemours, which can pressure the stock as investors factor in the cash outflows.

    It finalizes a major liability that affects CC's financial obligations and investor sentiment.